| Metric | Value ($ M) | Q1 FY26 | Q2 FY25 |
|---|---|---|---|
| Revenue | 17.0K | 13.3% | 10.2% |
| Total Income | 17.0K | 13.3% | 10.2% |
| Expenditure | 10.6K | 4.1% | 0.3% |
| PBT | 4.3K | 311.7% | 175.3% |
| Net Profit | 3.6K | 419.9% | 285.2% |
| OPM | 37.86% | 11.26pp | 6.13pp |
| NPM | 21.27% | 16.63pp | 15.18pp |
| EPS | 2.04 | 423.1% | 292.3% |
AbbVie Inc. Provides Q2 2026 and Full-Year 2026 Financial Guidance
07 Jul 2026 · 7 Jul, 1:47 am
Summary
AbbVie Inc. has provided updated financial guidance for the second quarter and full year of 2026, incorporating estimated acquired IPR&D and milestones expense. The company expects second-quarter 2026 adjusted diluted earnings per share to be in the range of $3.57 to $3.61, reflecting a $0.17 impact from these expenses. For the full year 2026, the adjusted diluted earnings per share guidance is now projected between $13.91 and $14.11, with total acquired IPR&D and milestones expense estimated at $1,035 million. The company notes that future acquired IPR&D and milestones expense beyond the second quarter cannot be reliably forecasted.
Key Highlights
- 1
AbbVie's full-year 2026 adjusted diluted earnings per share guidance range, including the impact of second-quarter 2026 acquired IPR&D and milestones expense, is $13.91 - $14.11.
- 2
AbbVie's second-quarter 2026 adjusted diluted earnings per share guidance range, including the impact of second-quarter 2026 acquired IPR&D and milestones expense, is $3.57 - $3.61.
- 3
Acquired IPR&D and milestones expense for the second quarter of 2026 is estimated at $291 million on a pre-tax basis.
- 4
This expense represents an unfavorable impact of $0.17 to both GAAP diluted earnings per share and adjusted non-GAAP diluted earnings per share for Q2 2026.
- 5
Full-year 2026 acquired IPR&D and milestones expense is projected to be $1,035 million, impacting the full-year adjusted diluted EPS range.
Management Comments
Scott T. Reents
The Company's 2026 adjusted diluted EPS guidance excludes any impact from acquired IPR&D and milestones expense that may be incurred beyond the second quarter of 2026, as both cannot be reliably forecasted.
Informational and educational content only. Not investment advice.